This is a translation of the Swedish press release 2022-09-15
In this falls investor letter (in Swedish) CEO Hanna Sjöström tells more about the upcoming rights issue that is guaranteed to 80 %, the acquisition of IP rights and the positive results from the first 50 infants in the clinical study on Ireland. In the investor letter the company’s three new board members are presented as well as ANMIRO’s strengthened position in the company. Neola Medical’s Clinical Manager, Tetiana Kovtiukh, is interviewed and tells more about her background in neonatology and the benefits she finds with Neola®.
Read the entire press release including the investor letter here (in Swedish): Press release